EGFR exon 20 insertion mutations were once considered untargetable. Today, breakthrough therapies like amivantamab and sunvozertinib are changing the landscape. Explore the science behind these advances and what they mean for cancer research.
MEK inhibitors have evolved from early research tools like U0126 to FDA-approved therapeutics. This guide explores the RAS-RAF-MEK-ERK pathway and the strategic use of MEK inhibitors in cancer therapy.
CDK4/6 inhibitors have transformed breast cancer treatment and are now expanding into NSCLC, melanoma, and glioblastoma. Discover the mechanisms, resistance pathways, and research applications of palbociclib, ribociclib, and abemaciclib.
Comprehensive guide to BTK inhibitor evolution: from ibrutinib’s covalent mechanism through selective second-generation compounds to non-covalent approaches targeting C481 resistance mutations.
Explore the historical barriers to KRAS inhibition, the G12C breakthrough with sotorasib, and emerging strategies for targeting G12D and other mutations. A comprehensive guide for researchers investigating mutant-selective KRAS biology.
